A study published in Lancet’s EClinical Medicine journal revealed that Covid-19 patients who are already on anticoagulation therapy taking blood thinners had almost half the risk of mortality and nearly 43% lower risk of hospital admission.
This study was conducted by the University of Minnesota, University of Basel, Switzerland and Columbia University in the US, involving 6,195 patients. It was recorded that patients who were on blood thinners before contracting covid-19 were admitted less to the hospital though they were older and having more chronic medical conditions.
The study focused on the patients who were over the age of 18 years diagnosed with covid-19 in a prospective cohort study from 4 March to 27 August, 2020 and was based on data from 12 hospitals and 60 clinics of M Health Fairview.
The researchers also found that the relationship between ninety day anticoagulation therapy among patients before covid-19 diagnosis and the risk for hospitalization and mortality and inpatient anticoagulation therapy and mortality risk.
“Blood thinners — regardless of if they are being used before being infected with covid-19 or started when admitted to the hospital for treatment of covid-19 reduce deaths by almost half," the study said.